Q4 2024 · 13F-HR
Kynam Capital Management, LPholdings as filed
Filed 2025-02-14 · accession 0001085146-25-001501
$1.69B
Reported value
30
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 632307104 | NTRA | NATERA INC | $320.1M | 18.9% | 2,022,098 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $191.3M | 11.3% | 2,336,796 | Common | SOLE |
| 78462F103 | SPY | SPDR S&P 500 ETF TR | $175.8M | 10.4% | 300,000 | PUT | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $128.0M | 7.56% | 5,064,207 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $112.6M | 6.66% | 8,520,000 | Common | SOLE |
| 268158201 | DVAX | DYNAVAX TECHNOLOGIES CORP | $83.8M | 4.95% | 6,560,835 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $72.3M | 4.27% | 2,519,705 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $71.0M | 4.20% | 9,105,000 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $68.3M | 4.04% | 9,085,368 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $63.8M | 3.77% | 3,326,262 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $61.7M | 3.64% | 1,457,910 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $60.6M | 3.58% | 4,899,497 | Common | SOLE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $43.6M | 2.57% | 1,756,158 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $36.2M | 2.14% | 1,225,576 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $33.2M | 1.96% | 4,994,090 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $31.4M | 1.86% | 1,802,750 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $26.7M | 1.58% | 2,266,328 | Common | SOLE |
| 46333X108 | IRWD | IRONWOOD PHARMACEUTICALS INC | $20.8M | 1.23% | 4,685,563 | Common | SOLE |
| 901384107 | TSVT* | 2SEVENTY BIO INC | $17.5M | 1.03% | 5,953,825 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $15.3M | 0.90% | 1,252,738 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $15.1M | 0.89% | 390,792 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $7.4M | 0.44% | 530,478 | Common | SOLE |
| 12233L206 | BNR | BURNING ROCK BIOTECH LTD | $6.7M | 0.40% | 994,883 | Common | SOLE |
| 869367102 | — | SUTRO BIOPHARMA INC | $6.7M | 0.40% | 3,641,447 | Common | SOLE |
| 023111206 | — | AMARIN CORP PLC | $6.0M | 0.36% | 12,414,628 | Common | SOLE |
| N71542109 | PRQR | PROQR THRAPEUTICS N V | $4.6M | 0.27% | 1,750,000 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $4.1M | 0.24% | 1,000,000 | Common | SOLE |
| 142038108 | CRBU | CARIBOU BIOSCIENCES INC | $3.8M | 0.23% | 2,406,147 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $2.7M | 0.16% | 847,366 | Common | SOLE |
| 28658R106 | CLYM | CLIMB BIO INC | $984,600 | 0.06% | 547,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.